Comparative Pharmacology
Head-to-head clinical analysis: CREXONT versus STALEVO 150.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CREXONT versus STALEVO 150.
CREXONT vs STALEVO 150
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbidopa-levodopa combination; levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine in the brain, restoring dopaminergic neurotransmission. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa's central availability and reducing peripheral side effects.
Stalevo 150 is a combination of carbidopa, levodopa, and entacapone. Levodopa is converted to dopamine in the brain, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its bioavailability. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), reducing peripheral metabolism of levodopa to 3-O-methyldopa.
For Parkinson's disease: Oral, one capsule of CREXONT (carbidopa 35 mg and levodopa 245 mg extended-release) three times daily initially; may titrate based on response and tolerability. Maximum daily dose: eight capsules (carbidopa 280 mg, levodopa 1960 mg).
One tablet orally three times daily. Each tablet contains 150 mg levodopa, 37.5 mg carbidopa, and 200 mg entacapone.
None Documented
None Documented
Levodopa: terminal half-life approximately 1.5 hours (0.75–1.5 h) for immediate-release formulations; with carbidopa co-administration, the half-life is prolonged to about 2 hours. Carbidopa: plasma half-life about 2-3 hours. The short half-life necessitates frequent dosing or extended-release formulations like CREXONT to maintain therapeutic levels.
Levodopa (with carbidopa): ~1.5-2 hours. Carbidopa: ~1-2 hours. Entacapone: ~0.4-0.7 hours (short half-life; not primary determinant of dosing interval). Clinically, levodopa half-life determines dosing frequency for motor fluctuations.
Carbidopa and levodopa are excreted primarily via renal elimination. Carbidopa is excreted largely unchanged (70%) in urine, with the remainder as metabolites. Levodopa is extensively metabolized; its metabolites (including dopamine, 3-O-methyldopa, and others) are excreted renally, accounting for 80% of a dose, with about 20% appearing in feces.
Carbidopa and levodopa are primarily excreted renally. Levodopa: ~70-80% renal, with metabolites including 3-O-methyldopa. Carbidopa: ~50-70% renal, with ~30% fecal. Entacapone: ~90% fecal (mainly as metabolites), ~10% renal.
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent